Imidazoline receptors: Basic knowledge, recent advances and future prospects for therapy and diagnosis

Drugs of the Future

Volumn 22, Issue 7, 1997, Pages 757-772

  Molderings, Gerhard J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ATIPAMEZOLE; CIRAZOLINE; CLONIDINE; IDAZOXAN; IMIDAZOLINE RECEPTOR; RILMENIDINE;

ANTIARRHYTHMIC ACTIVITY; BLOOD PRESSURE; HUMAN; KIDNEY FUNCTION; MOLECULAR RECOGNITION; MOOD; NEUROPROTECTION; NONHUMAN; RECEPTOR AFFINITY; RECOGNITION; REVIEW; STOMACH ACID SECRETION;

EID: 0030759252     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (196)

1. 2-Adrenoceptors of rat and rabbit aortae differentiated by relative potencies, affinities and efficacies of imidazoline agonists. Br J Pharmacol 1982, 77: 169-76.
2. Bousquet, P., Feldman, J., Schwartz, J. Central cardiovascular effects of α-adrenergic drugs: Difference between catecholamines and imidazolines. J Pharmacol Exp Ther 1984, 230: 230-6.
3. Bousquet, P. Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol 1995, 26 (Suppl. 2): S1-6.
4. 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987, 134: 1-13.
5. 2-sites in the mammalian central nervous system. Pharmacol Ther 1995, 68: 175-208.
6. Parini, A., Moudanos, C.G., Pizzinat, N., Lanier, S.M. The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996, 17: 13-6.
7. Regunathan, S., Reis, D.J. Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 1996, 36: 511-44.
8. 3H]clonidine. Eur J Pharmacol 1994, 266: 25-33.
9. 2-adrenoceptors in the human central nervous system. Neuroscience 1994, 59: 589-98.
10. 2-adrenoceptor subtypes. J Pharmacol Exp Ther 1996, 279: 694-702.
11. 3H]imidazoline binding sites in rat kidney. Eur J Pharmacol 1995, 281: 341-6.
12. Atlas, D., Burstein, Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur J Biochem 1984, 144: 287-93.
13. Atlas, D. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. Biochem Pharmacol 1991, 41: 1541-9.
14. Meeley M.P., Ernsberger, P.R., Granata, A.R., Reis, D.J. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci 1986, 38: 1119-26.
15. 2-adrenoceptor binding sites. Br J Pharmacol 1995, 115: 689-95.
16. Singh, G., Hussain, J.F., MacKinnon, A., Brown, C.M., Kendall, D.A., Wilson, V.G. Evidence for the presence of a non-catecholamine, clonidine-displacing substance in crude, methanolic extracts of bovine brain and lung. Naunyn-Schmied Arch Pharmacol 1995, 351: 17-26.
17. Meeley, M.P., Hensley, M.L., Ernsberger, P., Felsen, D., Reis, D.J. Evidence for a bioactive clonidine-displacing substance in peripheral tissues and serum. Biochem Pharmacol 1992, 44: 733-40.
18. Dontenwill, M., Molines, A., Verdun, A., Bricca, G., Laurent, S., Bousquet, P. A circulating substance cross-reacting with antiimidazoline antibodies. Detection in serum in relation to essential hypertension. J Clin Invest 1993, 92: 1068-72.
19. Goldberg-Stern, H., Atlas, D., Schwartz, L. et al. Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid. Brain Res 1993, 601: 325-8.
20. Li, G., Regunathan, S., Barrow, C.J., Eshraghi, J., Cooper, R., Reis, D.J. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 1994, 263: 966-9.
21. Raasch, W., Regunathan, S., Li, G., Reis, D.J. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 1995, 56: 2319-30.
22. Li, G., Regunathan, S., Reis, D.J. Agmatine is synthesized by a mitochondrial arginine decarboxylase in rat brain. Ann NY Acad Sci 1995, 763: 325-9.
23. Sastre, M., Regunathan, S., Reis, D.J. Enzymatic hydrolysis of agmatine to putrescine in rat brain. Soc Neurosci Abstr 1995, 21: 810-5.
24. 2-adrenergic receptors. J Pharmacol Exp Ther 1995, 272: 581-7.
25. Chalmers, J., Pilowsky, P. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertension 1991, 9: 675-94.
26. Reis, J., Golanov, E., Ruggiero, D.A., Sun, M.K. Sympathoexcitatory neurons of the rostral ventrolateral medulla are oxygen sensors and essential elements in the tonic and reflex control of the systemic and cerebral circulations. J Hypertens 1994, 12: S159-80.
27. 1 receptors in the ventrolateral medulla and their role in cardiorespiratory control. In: Ventral Brainstem Mechanisms and Control of Respiration and Blood Pressure. Lung Biology in Health and Disease, 82. Trouth, C.O., Mills, R.M., Kiwull-Schone, H.F., Schlafke, M.E. (Eds.). Marcel Dekker: New York 1995, 319-58.
28. 2-Adrenergic receptors rather than imidazoline binding sites mediate the sympatholytic effect of clonidine in the rostral ventrolateral medulla. In: Ventral Brainstem Mechanisms and Control of Respiration and Blood Pressure. Lung Biology in Health and Disease, 82. Trouth, C.O., Mills, R.M., Kiwull-Schone, H.F., Schlifke, M.E. (Eds.). Marcel Dekker: New York 1995, 281-303.
29. Singewald, N., Philippu, A. Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. Trends Pharmacol Sci 1996, 17: 356-63.
30. Pineda, J., Ugedo, L., García-Sevilla, J.A. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: Possible involvement of imidazoline-preferring receptors. Naunyn-Schmied Arch Pharmacol 1993, 348: 134-40.
31. Ruiz-Ortega, J.A., Ugedo, L., Pineda, J., García-Sevilla, J.A. The stimulation effect of clonidine through imidazoline receptors on locus coerulus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin. Naunyn-Schmied Arch Pharmacol 1995, 352: 121-6.
32. 2-adrenoceptors: Involvement of imidazoline receptors located in the nucleus paragigantocellularis. Naunyn-Schmied Arch Pharmacol 1997, 355: 288-94.
33. Cedarbaum, J.M., Aghajanian, G.K. Noradrenergic neurons of the locus coeruleus: Inhibition by epinephrine and activation by the α-antagonist piperoxane. Brain Res 1976, 112: 413-9.
34. Head, G.A. Importance of imidazoline receptors in the cardiovascular actions of centrally acting antihypertensive agents. Ann NY Acad Sci 1995, 763: 531-40.
35. 1 agents: A new approach to the treatment of hypertension. Ann NY Acad Sci 1995, 763: 642-58.
36. Schäfer, S.G., Kaan, E.G., Christen, M.O., Low-Kröger, A., Mest, H.J., Molderings, G.J. Why imidazoline receptor modulator in the treatment of hypertension? Ann NY Acad Sci 1995, 763: 659-72.
37. 2-adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivatives. Naunyn-Schmied Arch Pharmacol 1991, 343: 271-82.
38. 2-adrenoceptors in the human heart: Discrimination by clonidine and moxonidine. Naunyn-Schmied Arch Pharmacol 1996, 354: 689-92.
39. 3H]-idazoxan binding sites in human cardiovascular tissues. Br J Pharmacol, in press.
40. Tseng, C.G., Appalsamy, M., Robertson, D., Mosqueda, G.R. Effects of nicotine on brain stem mechanisms of cardiovascular control. J Pharmacol Exp Ther 1993, 265: 1511-8.
41. Kreisberg, G.A., Diamant, S., Diamant, Y.Z., Atlas, D. Raised levels of an endogenous nonadrenergic substance in the serum of pregnancy-induced hypertension patients. Isr J Med Sci 1987, 23: 1194-7.
42. Boucher, M., Dubar, M., Chassaing, C., Vivet, P., Duchene-Marullaz, P. Cardiac electrophysiological effects of rilmenidine, a novel antihypertensive agent, in the conscious dog: Comparison with clonidine. Life Sci 1994, 54: 381-7.
43. Hayashi, Y., Kamibayashi, T., Maze, M. et al. Role of imidazoline-preferring receptors in the genesis of epinephrine-induced arrhythmias in halothane-anesthetized dogs. Anesthesiology 1993, 78: 524-30.
44. Mammoto, T., Kamibayashi, T., Hayashi, Y., Yamatodani, A., Takada, K., Yoshiya, I. Antiarrhythmic action of rilmenidine on adrenaline-induced arrhythmia via central imidazoline receptors in halothane-anaesthetized dogs. Br J Pharmacol 1996, 117: 1744-8.
45. Roegel, J.Ch., Yannoulis, N., De Jong, W., Monassier, L., Feldman, J., Bousquet, P. Inhibition of centrally induced ventricular arrhythmias by rilmenidine and idazoxan. Naunyn-Schmied Arch Pharmacol 1996, 354: 598-605.
46. Roegel, J.C., de Jong, W., Monassier, L., Feldman, J., Bousquet, P. Comparative effects of idazoxan, prazosin, and yohimbine on coronary ligation-induced arrhythmias in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1996, 27: 226-34.
47. Wang, H., Regunathan, S., Ruggiero, D.A., Reis D.J. Production and characterization of antibodies specific for the imidazoline receptor protein. Mol Pharmacol 1993, 43: 509-15.
48. 2 receptora, on glial fibrillary acidic protein concentration. Eur J Pharmacol 1995, 280: 205-10.
49. 3H]idazoxan. Neurosci Lett 1995, 184: 133-6.
50. Kamibayashi, T., Mammoto, T., Hayashi, Y. et al. Further characterization of the receptor mechanism involved in the anti-dysrhythmic effect of dexmedetomidine on halothane/epinephrine dys-rhythmias in dogs. Anesthesiology 1995, 83: 1082-9.
51. Allan, D.R., Penner, S.B., Smyth, D.D. Antagonism by idazoxan at low dose but not high dose, of the natriuretic action of moxonidine. Br J Pharmacol 1996, 117: 29-34.
52. Boucher, M., Chassaing, C., Chapuy, E. Cardiac electrophysiologic effects of alinidine, a specific bradycardic agent, in the conscious dog: Plasma concentration-response relations. J Cardiovasc Pharmacol 1995, 25: 229-33.
53. Challinor-Rogers, I.L., Hay, T.K.C., McPherson, G.A. Comparison of the cromakalim antagonism and bradycardic actions of a series of novel alinidine analogues in the rat. Naunyn-Schmied Arch Pharmacol 1994, 350: 158-66.
54. Li, G.G., Rand, M.J. Rilmenidine differs from clonidine in that it lacks histamine-like activity. J Pharm Pharmacol 1989, 41: 464-8.
55. Martínez-Mir, M.I., Donate, F., Están, L., Morales-Olivas, F.J., Rubio, E. Study on the histamine-like activity of guanfacine. J Pharm Pharmacol 1990, 42: 591-2.
56. 1-adrenoceptor-mediated contraction of isolated thoracic aortae of the guinea-pig. Pharmacology 1939, 39: 373-82.
57. Sanders, J., Miller, D., Patil, P.N. α-Adrenergic and histaminergic effects of tolazoline-like imidazolines. J Pharmacol Exp Ther 1975, 195: 362-71.
58. Michel, M.C., Rump, L.C. α-Adrenergic regulation of human renal function. Fundam Clin Pharmacol 1996, 10: 493-503.
59. 3H]-rauwolscine in the kidney of the dog. Clin Exp Pharmacol Physiol 1994, 21: 649-58.
60. 2-adrenergic binding sites in basolateral membranes from human kidney. Eur J Pharmacol - Mol Pharmacol Sect 1991, 206: 23-31.
61. Vigne, P., Lazdunski, M., Frelin, C. Guanabenz, guanochlor, guanoxon and idazoxan bind with high affinity to non-adrenergic sites in pig kidney membranes. Eur J Pharmacol 1989, 160: 295-8.
62. 2 imidazoline receptors. Brit J Pharmacol 1995, 116: 1737-44.
63. 2-adrenoceptor imidazoline binding site in rat kidney. Eur J Pharmacol 1996, 316: 359-68.
64. Coupry, I., Podevin, R.A., Dausse, J.P., Parini, A. Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney. Biochem Biophys Res Commun 1987, 147: 1055-60.
65. Coupry, I., Atlas, D., Podevin, R.A., Uzielli, I., Parini, A. Imidazoline-guanidinium receptive site in renal proximal tubule: Asymetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J Pharmacol Exp Ther 1990, 252: 293-9.
66. Ernsberger, P., Feinland, G., Meeley, M.P., Reis, D.J. Characterization and visualization of clonidine-sensitive imidazole sites in rat kidney which recognize clonidine-displacing substance. Am J Hypertens 1990, 3: 90-7.
67. Ivkovic, B., Bakthavachalam, V., Zhang, W. et al. Development of a high-affinity radioiodinated ligand for identification of imidazoline/guanidinium receptive sites (IGRS): Intratissue distribution of IGRS in liver, forebrain, and kidney. Mol Pharmacol 1994, 46: 15-23.
68. King, P.R., Suzuki, S., Nero, T.L., Gundlach, A.L., Louis, W.J. Molecular studies of α-2-adrenoceptor and catecholamine-insensitive imidazoline in rat brain and kidney. J Hypertens 1993, 11 (Suppl. 5): S160-1.
69. Limon, I., Coupry, I., Lanier, S.M., Parini, A. Purification and characterization of mitochondrial imidazoline-guanidinium receptive site from rabbit kidney. J Biol Chem 1992, 267: 21645-9.
70. 3H]idazoxan label different populations of imidazoline sites on rat kidney. Eur J Pharmacol 1993, 232: 79-87.
71. 1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential. Clin Exp Pharmacol Physiol 1996, 23: 845-54.
72. Allan, D.R., Penner, S.B., Smyth, D.D. Renal imidazoline preferring sites and solute excretion in the rat. Br J Pharmacol 1993, 108: 870-5.
73. Li. P., Smyth, D.D. Suppressed renal response to 2,6-dimethyl clonidine but not clonidine in one kidney-one clip hypertensive rats. J Pharmacol Exp Ther 1993, 267: 1395-400.
74. 2-adrenoceptor agonists on water and solute excretion in the rat: Two sites and/or receptors? J Pharmacol Exp Ther 1992, 261: 1080-6.
75. Blandford, D.E., Smyth, D.D. Potentiation of the natriuretic effect of clonidine following indomethacin in the rat. Can J Physiol Pharmacol 1991, 69: 1196-203.
76. 2-adrenoceptor sites. Br J Pharmacol 1996, 119: 663-70.
77. Darkwa, F.K., Smyth, D.D. Inhibition of the natriuretic action of the imidazoline receptor agonist moxonidine by indomethacin in the rat. Pharmacology 1995, 51: 347-55.
78. 1-imidazoline receptor-selective compounds mediate natriuresis in the rat. J Cardiovasc Pharmacol 1995, 26 (Suppl. 2): S63-7.
79. 1 sites): Putative G-protein-linked receptors. FASEB J 1991, 5: A1066.
80. 1-imidazoline sites in bovine adrenal medullary membranes. Naunyn-Schmied Arch Pharmacol 1993, 348: 70-6.
81. 1-Imidazoline receptors. Definition, distribution, and transmembrane signaling. Ann NY Acad Sci 1995, 763: 22-42
82. Wiecek, A., Fliser, D., Nowicki, M., Ritz, E. Effect of moxonidine on urinary electrolyte excretion and renal haemodynamics in man. Eur J Clin Pharmacol 1995, 48: 203-8.
83. 2 binding sites. Naunyn-Schmied Arch Pharmacol 1996, 354: 245-52.
84. 3H]clonidine binding sites in rat stomach: High affinity of imidazolines, guanidines and sigma ligands. Naunyn-Schmied Arch Pharmacol 1995, 351: 561-4.
85. Reis, D.J., Regunathan, S., Meeley, M.P. Imidazoline receptors and clonidine-displacing substance in relationship to control of blood pressure, neuroprotection, and adrenomedullary secretion. Am J Hypertens 1992, 5: 51S-7S.
86. Ohara-Imaizumi, M., Miyakawa, Y., Kumakura, K. Pertussis toxin attenuates clonidine inhibition of catecholamine release in adrenal chromaffin cells. Neurosci Lett 1988, 93: 294-9.
87. Ohara-Imaizumi, M., Kumakura, K. Effects of imidazole compounds on catecholamine release in adrenal chromaffin cells. Cell Mol Neurobiol 1992, 12: 273-83.
88. 2-Adrenoceptors do not regulate catecholamine secretion by bovine medullary cells: A study with clonidine. Mol Pharmacol 1986, 29: 134-41.
89. 2-adrenoceptor agonists of the secretion of catecholamines from isolated adrenal medullary cells. Naunyn-Schmied Arch Pharmacol 1983, 324: 15-9.
90. Wan, D.C.C., Powis, D.A., Marley, P.D., Livett, B.G. Effects of α-and β-adrenoceptor agonists and antagonists on ATP and catecholamine release and desensitization of the nicotinic response in bovine adrenal chromaffin cells. Biochem Pharmacol 1988, 37: 725-36.
91. Cull-Candy, S.G., Mathie, A., Powis, D.A. Acetylcholine receptor channels and their block by clonidine in cultured bovine chromaffin cells. J Physiol 1988, 402: 255-78.
92. Musgrave, I.F., Krautwurst, D., Hescheler, J., Schultz, G. Clonidine and cirazoline inhibit activation of nicotinic channels on PC-12 cells. Ann NY Acad Sci 1995, 763: 272-82.
93. ATP channels in insulin-secreting cells. Eur J Pharmacol 1991, 204: 41-8.
94. Dunne, M.J. Block of ATP-regulated potassium channels by phentolamineand other α-adrenoceptor antagonists. Br J Pharmacol 1991, 103: 1847-50.
95. +channels in mouse pancreatic B-cells. Br J Pharmacol 1991, 104: 385-90.
96. 2-adrenoceptors and imidazoline-binding sites in the control of insulin secretion. Clin Sci 1993, 85: 671-7.
97. Berdeu, D., Gross, R., Ribes, G., Loubatieres-Mariani, M.M., Bertrand, G. Effects of imidazolines and derivates on insulin secretion and vascular resistance in perfused rat pancreas. Eur J Pharmacol 1994, 254: 119-25.
98. + channels in pancreatic B-cells. Br J Pharmacol 1992, 107: 8-14.
99. 2-adrenoceptor antagonist. Eur J Pharmacol 1994, 254: 27-33.
100. Schulz, A., Hasselblatt, A. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn-Schmied Arch Pharmacol 1989, 340: 321-7.
101. 2-adrenoceptors are blocked. Naunyn-Schmied Arch Pharmacol 1989, 340: 712-4.
102. Shepherd, R.M., Hashmi, M.N., Kane, C., Squires, P.E., Dunne, M.J. Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: Implications for stimulus response coupling of insulin release. Br J Pharmacol 1996, 119: 911-6.
103. Challinor, J.I., McPherson, G. A. Evidence that imidazol(id)ineand sulphonylurea-based antagonists of cromakalim act at different sites in the rat thoracic aorta. Clin Exp Pharmacol Physiol 1993, 20: 467-75.
104. + channels in pancreatic B-cells. Exp Clin Endocrinol 1995, 103: 42-5.
105. Schwanstecher, M., Hasselblatt, A. The imidazoline compound phentolamine stimulates insulin release in a way different from that of sulfonylureas. Naunyn-Schmied Arch Pharmacol 1991, 344(Suppl. 2): R134.
106. Berdeu, D., Gross, R., Puech, R., Loubatieres-Mariani, M.M., Betrand, G. Evidence for two different imidazoline sites on pancreatic B cells and vascular bed in rat. Eur J Pharmacol 1995, 275: 91-8.
107. Ibbotson, T., Edwards, G., Weston, A.H. Antagonism of levcromakalim by imidazoline and guanidine derivatives in rat portal vein: Involvement of the delayed rectifier. Br J Pharmacol 1993, 110: 1556-64.
108. Okumura, K., Ichihara, K., Nagasaka, M. Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein. Eur J Pharmacol 1992, 215: 253-7.
109. + channels. Eur J Pharmacol 1992, 211: 87-95.
110. Wickenden, A.D., Prior, H., Kelly, E., Russell, K., Puocher, S.M., Kumar, K. The effects of pharmacological modulation of K-ATP on the guinea-pig isolated diaphragm. Eur J Pharmacol 1996, 302: 79-88.
111. ATP channels in guinea pig ventricular myocytes. Eur J Pharmacol 1995, 285: 309-12.
112. Bang, L., Nielsen-Kudsk, J.E. Smooth muscle relaxation and inhibition of responses to pinacidil and cromakalim induced by phentolamine in guinea-pig isolated trachea. Eur J Pharmacol 1992, 211: 235-41.
113. 2-sites. Br J Pharmacol 1994, 112: 1065-70.
114. 2 receptora. Eur J Pharmacol 1994, 262: 41-8.
115. Olmos, G., Ribera, J., García-Sevilla, J.A. Imidazoli(di)ne compounds interact with the phencyclidine-site of N-methyl-D-aspartate receptors in the rat brain. Eur J Pharmacol 1996, 310: 273-6.
116. Sjöholm, A. Effects of secretagogues on insulin biosynthesis and secretion in polyamine-depleted pancreatic B-cells. Am J Physiol-Cell Physiol 1996, 39: C1105-10.
117. Bhandare, P.N., Rataboli, P.V., D'Souza, R.S.D. Dual action of clonidine on ethanol-induced gastric lesions: Is the imidazoline-preferring receptor involved? Eur J Pharmacol 1991, 199: 243-5.
118. Del Tacca, M., Soldani, G., Bernardini, C., Martinoffi, E., Impicciatore, M. Pharmacological studies on the mechanisms underlying the inhibitory and excitatory effects of clonidine on gastric acid secretion. Eur J Pharmacol 1982, 81: 255-61.
119. 2 receptor antagonists on acid secretion stimulated by imidazoline derivatives in isolated parietal cells. Eur J Pharmacol 1987, 144: 67-76.
120. Medgett, I.C., McCulloch, M.W. Effects of clonidine, guanfacine and three imidazoline derivatives related to clonidine on blood pressure, heart rate and gastric secretion in the anaesthetized rat. Arch Int Pharmacodyn 1979, 240: 158-68.
121. Tesson, F., Limon, I., Parini, A. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive sites. Eur J Pharmacol 1992, 219: 335-8.
122. 2 imidazoline and σ-binding sites in rat and human stomach membranes: Pharmacological characterization and potential functional relevance. Submitted 1997.
123. 2-adrenergic receptors: Implications for depression. Crit Rev Neurobiol 1994, 9: 29-66.
124. 1-imidazoline sites. J Pharmacol Exp Ther 1993, 264: 172-82.
125. 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. Biochem Pharmacol 1991, 42: 569-84.
126. 1-imidazoline binding sites are elevated in depression but not generalizad anxiety disorder. J Psychiatr Res 1996, 30: 147-68.
127. 1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res 1996, 30: 169-84.
128. 2-adrenergic binding in platelets of women with dysphoric premenstrual syndromes. Biol Psychiatry 1993, 34: 676-86.
129. 3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol Psychiatry 1993, 34: 498-501.
130. Diamant, S., Eldar-Geva, T., Atlas, D. Imidazoline binding sites in human placenta: Evidence for heterogeneity and a search for physiological function. Br J Pharmacol 1992, 106: 101-8.
131. 2-imidazoline sites. Naunyn-Schmied Arch Pharmacol 1994, 350: 252-7.
132. 3H]idazoxan in the rabbit urethral smooth muscle. Pharmacological and biochemical characterization. Biochem Pharmacol 1991, 41: 701-7.
133. 2-adrenoceptors? Eur J Pharmacol 1990, 190: 203-15.
134. 2-type receptors: Pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 1993, 109: 625-31.
135. Lanier, S.M., Ivkovic, B., Singh, I., Neumeyer, J.L., Bakthavachalam, V. Visualization of multiple imidazoline/guanidinium-receptive sites. J Biol Chem 1993, 268: 16047-51.
136. Tesson, F., Buus, C.P., Lemoine, A., Pegorier, J.P., Parini, A. Subcellular distribution of imidazolme-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. J Biol Chem 1991, 266: 155-60.
137. 2 sites. J Pharmacol Exp Ther 1995, 272: 681-8.
138. +. J Pharmacol Exp Ther 1996, 276 359-64.
139. Lanier, B., Raddatz, R., Bakthavachalam, V., Coupry, I., Neumeyer, J.L., Lanier, S.M. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit. Mol Pharmacol 1995, 48: 703-10.
140. Raddatz, R., Parini, A., Lanier, S.M. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J Biol Chem 1995, 270: 27961-8.
141. 2-imidazolone binding sites on monoamine oxidases. J Biol Chem 1995, 270: 9856-61.
142. 2 with monoamine oxidase-B sites. J Neurochem 1993, 61: 881-9.
143. 3H]-idazoxan binding sites in the rat brain. Br J Pharmacol 1993, 108: 597-603.
144. Sannajust, F., Head, G.A. Involvement of imidazoline-preferring receptors in regulation of sympathetic tone. Am J Cardiol 1994, 74: 7-19A.
145. Escribá, P.V., Sastre, M., Wang, H., Regunathan, S., Reis, D.J., García-Sevilla, J.A. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci Lett 1994, 178: 81-4.
146. 3H]-idazoxan binding sites. Br J Pharmacol 1996, 118: 1-8.
147. Escribá, P.V., Ozaita, A., Miralles, A., Reis, D.J., García-Sevilla, J.A. Molecular characterization and isolation of a 45-kilodalton imidazoline receptor protein from the rat brain. Mol Brain Res 1995, 32: 187-96.
148. Greney, H., Bennai, F., Molines, A., Belcourt, A., Dontenwill, M., Bousquet, P. Isolation of a human cerebral imidazoline-specific binding protein. Eur J Pharmacol 1994, 265: R1-2.
149. 2-imidazoline receptor subtypes. Naunyn-Schmied Arch Pharmacol 1996, 354: 709-16.
150. 2 imidazoline affinity in rat kidney. Br J Pharmacol 1995, 115 (Suppl.): 72P.
151. Gilad, G.M., Salame, K., Rabey, J.M., Gilad, V.H. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 1996, 58: PL41-6.
152. 2-adrenoceptor antagonist idazoxan: Influence of time of administration and possible mechanisms of action. J Cereb Blood Flow Metab 1990, 10: 885-94.
153. Maiese, K., Pek, L., Berger, S.B., Reis, D.J. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J Cereb Blood Flow 1992, 12: 53-63.
154. Siesjö, B.K. Pathophysiology and treatment of focal cerebral ischemia, I: Pathophysiology. J Neurosurg 1992, 77: 169-84.
155. Auguet, M., Viossat, I., Marin, J.G., Chabrier, P.E. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 1995, 69: 285-7.
156. Griffiths, M.J.D., Messent, M., MacAllister, R.J., Evans, T.W. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993, 110: 963-8.
157. Mayer, B., Klatt, P., Werner, E.R., Schmidt, K. Identification of imidazole as a L-arginine-competitive inhibitor of porcine brain nitric oxide synthase. FEBS Lett 1994, 350: 199-202.
158. Gilad, G.M., Gilad, V.H. Commentary polyamines in neurotrauma: Ubiquitous molecules in search of a function. Biochem Pharmacol 1992, 44: 401-7.
159. Oderfeld-Nowak, B., Bacia, A., Gardkowska, M. et al. In vivo activated brain astrocytes may produce and secrete nerve growth factor-like molecules. Neurochem Int 1992, 21: 455-61.
160. Olmos, G., Alemany, R., Escribá, P.V., García-Sevilla, J.A. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br J Pharmacol 1994, 111: 997-1002
161. Regunathan, S., Feinstem, D.L., Reis, D.J. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J Neurosci Res 1993, 34: 681-8.
162. 2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci Lett 1993, 160: 109-12.
163. Regunathan, S., Feinstein, D.L., Raasch, W., Reis, D.J. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. NeuroReport 1995, 6: 1897-900.
164. Uhlen, S., Nässtrom, J., Post, C., Wikberg, J.E.S. Guanfacine inhibits excitatory amino acid release from rat cerebral cortex through a non-adrenergic mechanism. Pharmacol Toxicol 1989, 65: 357-61.
165. Kamisaki, Y., Hamahashi, T., Hamada, T., Maeda, K., Itoh, T. Presynaptic inhibition by clonidine of neurotransmitter amino acid release in various brain regions. Eur J Pharmacol 1992, 217: 57-63.
166. Tingley, F.D., Arneric, S.P. Evidence for clonidine presynaptically modulating amino acid release in the rostral ventral medulla: Role in hypertension. Brain Res 1990, 537: 175-81.
167. Ernsberger, P., Giuliano, R., Willette, R.N., Reis, D.J. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990, 253: 408-18.
168. Piletz, J.E., Sletten, K. Nonadrenergic imidazoline binding sites on human platelets. J Pharmacol Exp Ther 1993, 267: 1493-502.
169. 3H]rilmenidine in membranes from rat cerebral cortex. Eur J Pharmacol 1992, 218: 101-8.
170. 3H]Cirazoline as a tool for the characterization of imidazoline sites. Ann NY Acad Sci 1995, 763: 112-24.
171. 2-adrenoceptors. Eur J Pharmacol 1992, 215: 109-17.
172. 3H]atipamezole in S115 cells. Can J Physiol Pharmacol 1994, 72 (Suppl. 1): P13.1.13.
173. + transport and intracellular pH in renal proximal tubule cells. Biochim Biophys Acta 1990, 1024: 173-8.
174. 1 imidazoline preferring receptors: Two unique sites mediating natriuresis in the rat Cardiovasc Drugs Ther 1994, 8: 43-8.
175. 2-imidazoline binding sites. Naunyn-Schmied Arch Pharmacol 1995, 351: 507-16.
176. 2-receptor in rabbit iris. Naunyn-Schmied Arch Pharmacol 1993, 347: 394-401.
177. 2 specific ligands inhibit monoamine oxidase (MAO) and oxygen utilization in vitro and in vivo Naunyn-Schmied Arch Pharmacol 1996, 353 (Suppl.): R86.
178. 1) receptors in modulating aqueous humor dynamics. J Ocular Pharmacol 1994, 10: 393-402.
179. Ogidigben, M., Chu, T.C., Potter, D.E. Ocular actions of moxonidine: A possible role for imidazoline receptors. J Pharmacol Exp Ther 1994, 269: 897-904.
180. 2 imidazoline receptors, with effects suggesting a possible role for these receptors in the modulation of appetite. Br J Pharmacol 1995, 115 (Suppl.): 89P.
181. 2-imidazoline sites. Br J Pharmacol 1994, 111 (Suppl.): 298P.
182. Bousquet, P., Feldman, J., Atlas, D. An endogenous non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol 1986, 124: 167-70.
183. Synetos, C., Manolopoulous, V.G., Atlas, C., Pipilisynetos, E. Human plasma-derived material with clonidine displacing substance (CDS)-like properties contracts the isolated rat aorta. J Auton Pharmacol 1991, 11: 343-52.
184. Regunathan, S., Meeley, M.P., Reis, D.J. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol Pharmacol 1991, 40: 884-8.
185. Felsen, D., Ernsberger, P., Meeley, M.P., Reis, D.J. Clonidine displacing substance is biologically active on smooth muscle. Eur J Pharmacol 1987, 142: 453-5.
186. Berdeu, D., Puech, R., Loubatieres-Mariani, M.M., Bertrand, G. Agmatine is not a good candidate as endogenous ligand for imidazoline sites of pancreatic B cells and vascular bed. Eur J Pharmacol 1996, 308: 301-4.
187. Sener, A., Lebrun, P., Blachier, F., Malaisse, W.J. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine. Biochem Pharmacol 1989, 38: 327-30.
188. Galea, E., Regunathan, S., Eliopoulos, V., Feinstein, D.L., Reis, D.J. Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996, 316: 247-9.
189. Regunathan, S., Youngson, C., Raasch, W., Wang, H., Reis, D.J. Imidazoline receptors and agmatine in blood vessels: A novel system inhibiting vascular smooth muscle proliferation. J Pharmacol Exp Ther 1996, 276: 1272-82.
190. Kolesnikov, Y., Jain, S., Pasternak, G.W. Modulation of opioid analgesia by agmatine. Eur J Pharmacol 1996, 296: 17-22.
191. Gao, Y., Gumusel, B., Koves, G. et al. Agmatine: A novel endogenous vasodilator substance. Life Sci 1995, 57: PL83-6.
192. Sun, M.K., Regunathan, S., Reis, D.J. Cardiovascular responses to agmatine, a clonidine-displacing substance, in anesthetized rat. Clin Exp Hypertens 1995, 17: 115-28.
193. Szabo, B., Urban, R., Limberger, N., Starke, K. Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits. Naunyn-Schmied Arch Pharmacol 1995, 351: 268-73.
194. Glavin, G.B., Carlisle, M.A., Smyth, D.D. Agmatine, an endogenous imidazoline receptor agonist, increases gastric secretion and worsens experimental gastric mucosal injury in rats. J Pharmacol Exp Ther 1995, 274: 741-4.
195. Loring, R.H. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 1990, 99: 207-11.
196. Kaan, E.C., Brückner, R., Frohly, P., Tulp, M., Schäfer, S.G., Ziegler, D. Effects of agmatine and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. Cardiovasc Risk Factors 1995, 5 (Suppl. 1): 19-27.